George Badescu

George Badescu serves as Chief Business Officer at Heidelberg Pharma AG. Heidelberg Pharma AG operates in the research sector with approximately 49.0 employees. The company is headquartered in London, England. Heidelberg Pharma AG generates annual revenue of 6555000.0.

Industry & Role Insights

• • MessageCEO tracks 2,961 executives in the research sector.
• • 10,137 executive contacts are available in England.
• • Our database includes 201,469 c suite-level executives.

SendInBlue Mobile Friendly Joomla Apache Remote

onkologie adc atac amanitin biotechnology research adc technology antibody-drug conjugates cancer therapy targeted therapy atac technology tumor resistance oncology clinical development bioconjugation biopharmaceuticals solid tumors hematological cancers innovative drugs drug development toxins drug delivery systems payloads cancer treatment therapeutic candidates bcma-atac cd37-atac psma-atac gcc-adc clinical trials fda approval orphan drug designation preclinical studies biomarkers rna polymerase ii apoptosis immuno-oncology therapeutic modalities drug candidates phase i trials phase ii trials molecular targets toxicology studies pharmacokinetics biological activity tumor microenvironment receptor-targeted therapy collaborative studies biotechnology partnerships drug efficacy serine protease inhibitors covid-19 treatment clinical efficacy preclinical trials pharmaceutical research hospital & health care health care health wellness & fitness

SN

Srikanth Nandiraju Chief Technology Officer at 1Cell.Ai Inc.

SD

Surinnder Dang Chief Business Officer at 1Cell.Ai Inc.

M

Mark Chief Executive Officer at 23Strands

IT

Ilia Tikhomirov Chief Executive Officer at 35Pharma

AD

Alistair Draffan Chief Executive Officer at 360biolabs Pty Ltd

Outreach Guidance — research Sector

Executives like George Badescu in the research sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at Heidelberg Pharma AG.

George Badescu's Position in the MessageCEO Database

• •George Badescu is 1 of 1 verified executive contact we track at Heidelberg Pharma AG.
• •2,871 verified executive contacts in research are in the MessageCEO database.
• •10,040 verified executive contacts in England are in the database.
• •23 verified contacts work at research companies in the 49.0 employee range (same size as Heidelberg Pharma AG).

Executive contact data compiled from public business filings, LinkedIn public profiles, company press materials, and verified outbound email testing. We do not publish personal addresses or sensitive identifiers. Methodology & sources · Removal requests handled at /remove-info · Updated July 2026.

How do I reach George Badescu directly?

George Badescu's verified email address is available to MessageCEO Pro subscribers. They currently serve as Chief Business Officer at Heidelberg Pharma AG. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does George Badescu work for?

George Badescu is Chief Business Officer at Heidelberg Pharma AG, a company in the research sector with 49.0 employees. The company is based in London, England.

Can I pitch or sell to George Badescu?

As Chief Business Officer at Heidelberg Pharma AG, George Badescu is a key decision-maker in the research sector. MessageCEO Pro gives you verified email to reach George Badescu directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is George Badescu in?

George Badescu works in the research industry as Chief Business Officer at Heidelberg Pharma AG. MessageCEO provides verified contact information for executives across all major industries.

Is George Badescu's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. George Badescu's profile is kept up-to-date with the latest available information.

Last updated: July 24, 2026